Search…

Lates News

29/08/2025

According to the AI news of Every News, Guojin Securities released a research report on August 29, giving a buy rating to Bull Group (603195.SH). The rating reasons mainly include: 1) the traditional advantageous business is under short-term pressure due to external environment, while the performance of new energy and incubation businesses is outstanding; 2) short-term changes in business structure affect gross profit margin, but overall cost control is excellent; 3) the strategic layout is clear, and new businesses and internationalization will open up future growth space. (Daily Economic News)

Latest

1 m ago

Cao Qingyao, a counselor to the Chongqing Municipal Government, is under review and investigation.

2 m ago

According to Every Day Economic News, Pacific Securities released a research report on August 29th, giving a buy rating to Haoyuan Medicine (688131.SH). The rating reasons mainly include: 1) rapid growth of front-end business, continuous expansion of product categories; 2) stable growth of back-end business, rapid growth in hand orders.

2 m ago

Every Economic AI Express, Pacific Securities released a research report on August 29, giving Xgimi Technology (688696.SH) a buy rating. The reasons for the rating mainly include: 1) The profit in Q2 2025 turned losses into gains, and the projector main business resumed steady performance; 2) The gross and net profit margins in Q2 2025 both increased, with a significant decrease in the sales expense ratio; 3) The car-mounted business achieved a breakthrough in mass production, and the brand continued to expand overseas. (Daily Economic News)

2 m ago

China antibody-B (03681.HK) completes the issuance of 24.9654 million subscribed shares.

2 m ago

Every AI Express, Pacific released a research report on August 29th, giving Ailis (688578.SH) a buy rating. The rating reasons mainly include: 1) Continuously improve marketing network and production capacity construction; 2) Smooth progress of domestic clinical projects under research; 3) Ailis cooperates with ArriVent to jointly promote overseas clinical trials of 2 rare mutations. (Daily Economic News)

See all latest